GlobalData on MSN5d
Vertex secures two FDA wins for cystic fibrosis, both with boxed warningsVertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
BX-004 is under development for the treatment of cystic fibrosis, non-cystic fibrosis bronchiectasis and resistant pseudomonas aeruginosa infections. It is administered as inhalational formulation.
Zacks.com on MSN4d
Vertex Secures FDA Approval for New Cystic Fibrosis Drug AlyftrekThe FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared ...
DelveInsight, a leader in healthcare competitive intelligence and consulting company, published a success study on Digital ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...
Whether you are dealing with severe consequences of cystic fibrosis or want to get ahead the symptoms, these tips will help.
A $42,000 grant from NASA and INBRE will further CF research, through a collaborative effort spanning to India and the United Kingdom.
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback